The pursuit of an HIV cure has hit a significant, if nuanced, milestone. Recent analysis of multiple clinical trials shows that broadly neutralizing antibodies (bnAbs) are dramatically extending the time it takes for the virus to rebound in people who stop antiretroviral therapy (ART), offering a tantalizing glimpse of potential long-term remission – and, ultimately, a cure. While not a cure *yet*, the consistency of these results across different studies is fueling optimism and reshaping the strategic approach to HIV eradication.
- Extended Remission: bnAb therapy is delaying viral rebound for months, even years, in some participants – far beyond the typical 2-4 weeks.
- Post-Intervention Controllers (PICs): A significant proportion of participants are now being classified as PICs, demonstrating a clear therapeutic effect beyond the rare naturally occurring Post-Treatment Controllers (PTCs).
- CD8 Cell Fitness is Key: Emerging research suggests the effectiveness of bnAbs is linked to the ‘fitness’ of the patient’s CD8 T cells, opening a new avenue for patient selection and treatment optimization.
For decades, the standard of care for HIV has been lifelong ART, which suppresses the virus but doesn’t eliminate it. The virus remains hidden in reservoirs within the body, ready to rebound if treatment is stopped. The idea behind bnAbs – antibodies that neutralize a wide range of HIV strains – is to keep the virus suppressed long enough for the immune system to potentially clear these reservoirs. The two bnAbs being studied, 3BNC117 (teropavimab) and 10-1074 (zinlirvimab), represent a major advance in antibody engineering, offering significantly broader neutralization than earlier antibody candidates. The fact that multiple trials, using slightly different approaches (including combining bnAbs with immune-boosting drugs), are yielding similar results is particularly encouraging. It suggests a fundamental biological principle is at play, rather than a fluke effect in a single study.
The Ragon Institute analysis highlights a crucial point: the duration of viral control isn’t uniform. While many participants experience delayed rebound (becoming PICs), a small but significant number are achieving remarkably long periods of remission – several years and counting. This variability is now being linked to the health and functionality of the patient’s CD8 T cells. Stronger, more ‘fit’ CD8 cells appear to be better able to control the virus in conjunction with bnAb therapy. This is a critical finding, as it shifts the focus from simply suppressing the virus to bolstering the body’s own immune defenses.
The Forward Look: The next 12-18 months will be pivotal. We can expect to see several key developments. First, larger and more rigorously designed clinical trials will be launched, specifically targeting individuals with high-fitness CD8 T cells. These trials will aim to confirm the link between CD8 cell function and treatment success. Second, researchers will be exploring ways to *improve* CD8 cell fitness – potentially through targeted therapies or vaccination strategies – to broaden the pool of patients who could benefit from bnAb therapy. Finally, the focus will increasingly turn to strategies for eliminating the remaining viral reservoir. bnAbs alone may not be enough to achieve a complete cure, but they could be a crucial component of a ‘shock and kill’ approach, where the virus is forced out of hiding and then eliminated by the immune system. The field is moving beyond simply managing HIV to actively pursuing its eradication, and these latest findings represent a significant step forward on that path.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
